key: cord-0858962-w2dwwqie authors: Wiseman, D. M.; Kory, P.; Mazzucco, D.; Ramesh, M. S. title: Preventing disease after exposure to COVID-19 using hydroxychloroquine: A summary of a protocol for exploratory re-analysis of age and time-nuanced effects. date: 2020-08-26 journal: nan DOI: 10.1101/2020.08.19.20178376 sha: 689f3683ee3342f677ccbc90637870b2900a1b61 doc_id: 858962 cord_uid: w2dwwqie BACKGROUND: A recently published randomized trial (Boulware et al., 2020, NCT04308668) of hydroxychloroquine (HCQ) for post-exposure prophylaxis found a reduction in Covid-19 of 17%. In the context of ambitious powering to detect a 50% reduction, this non-statistically significant finding could translate to a reduction of 22,000/130,828 cases (CDC 8/12/20) among US health care workers (HCW), impacting trajectory and resource utilization models that drive decisions on lockdowns and social distancing. Data found only in the appendix of Boulware et al. suggested greater differences in the effect of HCQ among sub-groups. There were reductions (36%) in younger (<35 years) and increases (110%) in older (>50 years) subjects. Our preliminary analysis revealed a significant negative correlation (slope -0.211, CI -0.328-0.094, p=0.016) between treatment lag and disease reduction, reaching 49% when initiated within one day (RR 0.51, CI 0.176-1.46, p=0.249). There were also differences in disease reduction by HCQ by type of exposure (HCW - 8% vs. household contacts - 31%; RR 0.691, CI 0.398-1.2). The definitions of exposure severity did not discriminate between the numbers or duration (> 10 minutes) of exposures. Differences between exposure types may result from younger HCW and higher risks in less trained household contacts with little access to advanced PPE. The ex-protocol use of zinc and ascorbic acid were likely confounders, as was the possibly active folate placebo. Exploratory reanalysis of the raw dataset may inform an age- and stage- nuanced approach to COVID-19 using HCQ testable by prospective studies and may provide insight into the various proposed mechanisms of HCQ. OBJECTIVES: To conduct an exploratory re-analysis of the de-identified raw dataset from a randomized study of the use of HCQ for post-exposure prophylaxis of COVID-19 with view to further defining: a) The time dependent effect of HCQ, b) The age dependent effect of HCQ; c) The sub-stratification of time- and age-dependent effects by exposure type and risk level, as well as by the use of zinc and ascorbic acid. d) The design of future clinical trials to test the hypotheses generated by this study. METHODS: Should granularity of data (by age, time-lag, level and type of exposure) be greater than that originally reported, Fisher Exact test will be used to compare the incidence of COVID-19 in HCQ- and control groups, for each sub-group stratification. Since the degree of loss of data granularity due to de-identification is yet unknown, exploratory analyses involving other demographic characteristics cannot be planned. Where sufficient data granularity exists, univariate regression analyses will be conducted to examine the effect of age- and time lag on any effect of HCQ. The possibility will be explored of conducting multivariate Cox regression analyses with propensity score matching to examine observational data relating to the use of zinc and ascorbic acid. This analysis will be expanded should a dataset from a similarly designed study (Mitja et al., 2020, NCT04304053), with directionally similar results, become available. This protocol was devised using the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) incorporating the WHO Trial Registration Data Set. Study Status: Protocol version 1.1, (August 19 2020) Protocol registered at: OSF Registries August 19 2020 Registration doi: https://doi.org/10.17605/OSF.IO/9RPYT Supplemental data not discussed in the main body of the published paper suggested greater reductions of COVID-19 in a number of sub-groups. There were reductions (36%) in younger (<35 years) and increases (110%) in older (> 50 years) subjects. This is consistent with the findings of an observational prophylaxis study involving mainly younger HCW in India. 5 Our preliminary analysis revealed a statistically significant negative correlation (slope -0.211, 95%CI -0.328-0.094, p=0.016, rho CI -1 to -0.42, confirmed independently 6 ) between treatment lag and reduction of COVID-19, reaching 49% when given within one day after exposure (RR 0.51, CI 0.176-1.46, p=0.249). The early use of HCQ is supported by mathematical modeling that considers the peaking of the viral load in the pharyngeal cavity and the effect of the drug to kill infected cells by enhancing cell-mediated immunity. 7 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 26, 2020. . There were also differences in development of COVID-19 by type of exposure (HCW vs. household; (OR 0.53, CI 0.299-0.94, p = 0.031) in the placebo group, with a small (8%) reduction in COVID-19 with HCQ in HCW, and a 31% reduction in the household group (RR 0.691, CI 0.398-1.2, p=0.24). The definitions of severity of exposure did not however discriminate between the numbers of exposures or durations longer than 10 minutes. Differences between the different exposure types may have been accounted for by a lower age in the HCW group and higher exposure risk in household contacts, who may have had less access to advanced PPE than HCW as well as to training on hygiene practices. Differences between exposure risk related to type of in hospital-assignment and household risk among UK HCW and likely use of PPE has been suggested to account for differences in rates of COVID-19 in a UK study. 8 The study also included observational data relating to use of zinc and Vitamin C. There was a higher incidence of symptoms when Vitamin C was used, both without (20.8% vs 11.2%, p=0.014) and with (14.3 vs. 10 .6%, p=0.33) HCQ. For zinc there was a similar relationship in the HCQ group, but not in the placebo group. Since details about timing, dose and reasons for self-medicating with these agents are unknown, these observational data confound the overall findings, as does the use of folate for the placebo. In silico analyses show that folate may interact with SARS-Cov-2. 9,10 In an observational study, blood folic acid levels were significantly lower in severe COVID-19 patients. 11 For some other viruses there may be an association between folate deficiency/ supplementation and disease severity/ amelioration/prevention -Zika 12 ; HPV 13, 14 ; HIV 15 . Accordingly, the now publicly released raw dataset may reveal important clues to inform an age-and stage-nuanced approach to COVID-19 using hydroxychloroquine testable by prospective studies. Data from a second 16 similarly designed study, with directionally similar results may soon become available for similar analyses. Further examination of these data may also provide insight into the various proposed mechanisms of HCQ. At early stages, consistent with incubation period estimates of 3-8 days 17 , HCQ alone may be effective in pre-emption because it interferes with viral attachment and initial infectivity. Using zinc (or Vitamin C) may be futile, ineffective or counterproductive in otherwise healthy individuals with no zinc dysregulation. HCQ may be sufficient in young people, however once infection has occurred, HCQ's actions as an ionophore 18 may be more important, and require the presence of zinc for viral inhibition. 19 To conduct more detailed analysis of the raw dataset relating the use of HCQ for post-exposure prophylaxis of COVID-19 with view to further defining: a) The time dependent effect of HCQ, on post exposure prophylaxis for COVID-19. b) The age dependent effect of HCQ, on post exposure prophylaxis for COVID-19. c) The sub-stratification of time-and age-dependent effects by exposure type and risk level, as well as by the use of zinc and ascorbic acid. d) The design of future clinical trials designed to test the hypotheses generated by this study. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 26, 2020. . https://doi.org/10.1101/2020.08.19.20178376 doi: medRxiv preprint METHODS: A post hoc exploratory re-analysis will be conducted of a dataset obtained from a randomized, controlled studies on the use of hydroxychloroquine to prevent COVID-19 after exposure, This analysis will be expanded should a dataset from a second similar study become available. The re-analysis will explore apparent exposure risk, age and time-nuanced effects of HCQ with three main hypotheses: a) That HCQ exerts a negative age-dependent effect in reducing COVID-19 when given prophylactically after exposure. b) The HCQ exerts a negative time-dependent effect in reducing COVID-19 when given prophylactically after exposure. c) That any age-and time-dependent effects of HCQ will be further dependent on type and risk level of exposure and the use of zinc or ascorbic acid. This protocol was devised using the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) 20, 21 incorporating the WHO Trial Registration Data Set 22 which it references. a) That HCQ exerts a negative age-dependent effect in reducing COVID-19 when given prophylactically after exposure. b) The HCQ exerts a negative time-dependent effect in reducing COVID-19 when given prophylactically after exposure. c) That any age-and time-dependent effects of HCQ will be further dependent on type and risk level of exposure and the use of zinc or ascorbic acid. This study is a post hoc exploratory analysis of a dataset obtained from an original study 1 that was a randomized, controlled, blinded clinical trial with a pragmatic design with participants from the USA and Canada. Part of the data related to the use of zinc and ascorbic acid which were observational in nature. Data from a similarly designed but open-label, cluster randomized study 16 conducted in Spain, if available, will be subjected to similar analyses. The original study 1 was a double-blinded placebo-controlled study. The second study 16 was an open-label, clusterrandomized trial. Details of blinding, implementation of allocation, enrollment, assignment of interventions and unblinding may be found in the publicly-released documentation for the original studies. No further blinding will be employed for the purposes of this exploratory re-analysis. The original stud(y/ies) were interventional studies that used COVID-19 related endpoints to compare the performance of two groups -HCQ treatment vs. or placebo-1 or no-16 treatment. The current protocol will further stratify data by age-, treatment-lag, exposure type and risk level and zinc and ascorbic acid use. Details of randomization are found in the publicly-released documentation for the original studies. No further randomization will be employed for the purposes of this exploratory re-analysis. Zinc and ascorbic acid were used in one study, 1 but this use was not part of the protocol and was uncontrolled. Accordingly, data concerning zinc and ascorbic acid is considered as retrospective and observational. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 26, 2020. . https://doi.org/10.1101/2020.08.19.20178376 doi: medRxiv preprint 3.1 The two studies have been published and examined along with their supplementary summary statistics released at the time of publication. 1 16 The raw dataset for the first 1 of these has been released and has been transmitted in email form to us by the original authors, but this has not yet been accessed. The raw dataset for the second study 16 has not been released. Accordingly, this protocol is being registered prior to accessing the data: As of the date of submission, the data exist, but have not been accessed by the sponsor or principal investigator. Once this protocol has been registered, the raw dataset will be downloaded and inspected. Other than the analyses already published by the original authors, further data patterns are unknown. Moreover, since there are a number of methods that may be used to de-identify data 23 and the level of data granularity is unknown, the type of analyses possible cannot yet be determined. Details of data collection procedures including inclusion and exclusion criteria are found in the publicly-released documentation for the original studies. No further data collection will be employed for the purposes of this exploratory re-analysis. Details of sample size are found in the publicly-released documentation for the original studies. The first study 1 had 414 and 407 subjects in the HCQ-treated and placebo arms respectively. The second study 16 had 1116 and 1198 subjects in the HCQ and no-treatment arms respectively. Sample size rationales are provided in the original studies. This exploratory study will examine smaller subgroups and without control over their size. The statistical challenges of performing sub-group analyses are well-known. 24 ,25 Not applicable The manipulated variable (treatment arm) employed in the original studies is: Treatment for post-exposure prophylaxis of COVID-19 with levels as: • Treatment with HCQ • No (or placebo) treatment Data will be stratified and sub-stratified by: • Subject age • Time between exposure to COVID-19 and treatment • Type of exposure (household vs. health worker contact) • Level of exposure risk • Treatment with zinc or ascorbic acid The primary outcomes defined in the original studies were: • Presence of COVID-19, based on symptom-based criteria with expert review. 1 • Presence of PCR-confirmed, symptomatic Covid-19 16 Secondary endpoints were: • Prevention of transmission of COVID-19 16 . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 26, 2020. . The presence of symptom-or test-based COVID-19 will be expressed a percentage of the number of subjects for each subgroup and Odds or Risk Ratios computed with 95% confidence intervals. Risk ratios may also be expressed as its complement, the reduction of risk. Fisher's Exact test will be used to compare the incidence of COVID-19 in HCQ-and control groups, for each subgroup stratification described above. Since it is as yet unknown how the raw data have been de-identified 23 and the level of data granularity is unknown, other possible analyses cannot yet be determined. Where sufficient data granularity exists, univariate regression analyses will be conducted to examine the effect of age-and time lag on any effect of HCQ. The possibility will be explored of conducting multivariate Cox regression analyses with propensity score matching to examine observational data relating to the use of zinc and ascorbic acid. See also comments received after version 1.0 of this protocol was registered from Dr. Boulware (section 5.6). Should the dataset become available for the second study, it may be possible to aggregate data with those from the first study. As this is an exploratory analysis, no adjustment will be made for the clustering used in the second study. Since it is as yet unknown how the raw data have been de-identified 23 and the level of data granularity is unknown, other possible analyses and the need for data transformation cannot yet be determined. Since all analyses performed in this protocol are exploratory in nature, p-values from two-tailed tests will be reported if < 0.1 without adjustment for multiple comparisons. 25 The ability to conduct the planned analyses will depend on the methods used to de-identify data and the level of granularity present in the raw data set: For example: • Data that are no more granular than is provided in the published studies will not be eligible for further analysis. As per the original studies, missing or incomplete data will not be included in the analyses. As this protocol is exploratory in nature, sensitivity analyses will not be conducted. Since it is as yet unknown how the raw data have been de-identified 23 and the level of data granularity is unknown, further exploratory analyses cannot yet be determined. However, the relationships between the primary outcomes and demographic variables, as well as exposure type and level will be explored. Subsequent to the registration (https://osf.io/4akug) of version 1.0 of this protocol, we received the following unsolicited but welcome suggestions from Dr. Boulware, the principal author of the first 1 of the studies considered in this protocol. a. "Along with doing the incorrect Watanabe linear regression analysis, consider doing the actual proper analysis for categorical data, which would be a logistic regression model with an interaction term for treatment group * exposure time group." Response: The ability to conduct this type of analysis will depend on the level of data granularity which is as of this protocol version (1.1) unknown to us. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 26, 2020. . The suggestion to pool the placebo data may be reasonable as there really should not be any difference by time and all we are seeing there is noise. However, there is still the possibility that folate has some activity [see 1.3] , in which case pooling may not be appropriate. This protocol has been registered with the Open Science Framework (OSF, Center for Open Science). This study has the internal identifier of SYN2001SYN. Contact for public and scientific queries: There are no secondary sponsors The original studies have been completed and their data published. 1,16 There is no external support for this study. The sponsor is entirely responsible for the design and conduct of this study. The sponsor and principal investigator have no financial or other conflicts of interest in the subject matter of this protocol. Analyses will be performed on a de-identified, publicly released dataset obtained from studies conducted under ethics committee supervision. No further Ethics Committee, IRB approval, informed consent or confidentiality provisions are required. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 26, 2020. . https://doi.org/10.1101/2020.08.19.20178376 doi: medRxiv preprint 6.7 Not applicable Not applicable No data entry is required. Microsoft Excel will be used for primary data manipulation. Vassar Stats (vassarstats.net/) will be used for confirmation of calculations. A study report will be complied and submitted for publication. Microsoft Excel files will be made available on request.to other investigators. Data will be summarized as part of the study publication. Consent materials: Not applicable Biological specimens: Not applicable The checklist for the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT) 20,21 was used to construct this protocol. As the SPIRIT checklist references (Item 2b) the WHO Trial Registration Data Set 22 , a cross reference is provided below for the 24-item WHO Data Set. Where there is no corresponding SPIRIT item, it is listed under SPIRIT Item 2b. Section numbers for the required item are indicated. Non-applicable items are marked "NA." . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 26, 2020. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 26, 2020. . https://doi.org/10.1101/2020.08.19.20178376 doi: medRxiv preprint Study setting 9 Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure) 6 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 26, 2020. . . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted August 26, 2020. . Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators) 6.2 Consent or assent 26a Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32) 6.6, NA 26b Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable 6.6, NA How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial 6.6, NA Financial and other competing interests for principal investigators for the overall trial and each study site 6.66.5 Access to data 29 Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators 6.9 Ancillary and post-trial care 30 Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation 6.8 NA Dissemination policy 31a Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions. 6.9 31b Authorship eligibility guidelines and any intended use of professional writers 1.2 31c Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code. Appendices Informed consent materials 32 Model consent form and other related documentation given to participants and authorised surrogates 6.11, NA Biological specimens 33 Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable 6.11, NA *It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons "Attribution-NonCommercial-NoDerivs 3.0 Unported" license. . CC-BY-NC 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted August 26, 2020. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. Reply Improving pragmatic clinical trial design using real-world data Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report Pre exposure Hydroxychloroquine use is associated with reduced COVID19 risk in healthcare workers Efficacy of Hydroxychloroquine as Prophylaxis for Covid-19 Pharmacokinetic Basis of the Hydroxychloroquine Response in COVID-19: Implications for Therapy and Prevention Differential occupational risks to healthcare workers from SARS-CoV-2: A prospective observational study Hispidin and Lepidine E: two Natural Compounds and Folic acid as Potential Inhibitors of 2019-novel coronavirus Main Protease (2019-nCoVMpro), molecular docking and SAR study. Current computer-aided drug design Repurposing Therapeutics for COVID-19: Supercomputer-Based Docking to the SARS-CoV-2 Viral Spike Protein and Viral Spike Protein-Human ACE2 Interface Clinical Characterization of 162 COVID-19 patients in Israel: Preliminary Report from a Large Tertiary Center Preventive effects of folic acid on Zika virus-associated poor pregnancy outcomes in immunocompromised mice Interactions between serum folate and human papillomavirus with cervical intraepithelial neoplasia risk in a Chinese population-based study Folate Deficiency Facilitates Genomic Integration of Human Papillomavirus Type 16 DNA In Vivo in a Novel Mouse Model for Rapid Oncogenic Transformation of Human Keratinocytes Poverty, folate deficiency, human immunodeficiency virus and ulcerated vulval sexually transmitted diseases in Jamaica A Cluster-Randomized Trial of Hydroxychloroquine as Prevention of Covid-19 Transmission and Disease Estimation of the incubation period of COVID-19 using viral load data Chloroquine is a zinc ionophore Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients SPIRIT 2013 statement: defining standard protocol items for clinical trials World Health Organization. WHO Trial Registration Data Set (Version 1.3.1) Guidance Regarding Methods for De-identification of Protected Health Information in Accordance with the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule Lagakos SW. The challenge of subgroup analyses--reporting without distorting